Form 4 for KLRS Kalaris Therapeutics, Inc.
Accepted 2024-01-08 00:00:00 ET · period of report 2024-01-04 · accession 0000950170-24-002935 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-01-08 | 2024-01-04 | KLRS | Brainard Diana | CEO, Dir | S - Sale | $0.64 | -1,664 | 873.2K | -0.2% | -$1,065 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-01-04 | S | D | 1,664 | $0.64 | 873,242 | D | — | — |